Skip to main content
. 2018 Apr 3;9(25):17711–17724. doi: 10.18632/oncotarget.24845

Table 5. Correlation between PIK3CA mutation status and clinicopathological factors in pre- and postmenopausal women.

Premenopausal Postmenopausal
Wild-type
(n = 31)
Mutant
(n = 29)
P Wild-type
(n = 73)
Mutant
(n = 71)
P
Age (years),
mean ± SD (range)
43.2 ± 5.9
(27–52)
45.4 ± 5.1
(35–56)
0.17 62.0 ± 8.2
(42–80)
63.8 ± 8.2
(47–84)
0.18
BMI,
mean ± SD (range)
21.8 ± 4.1
(15.2–32.9)
21.8 ± 3.4
(16.7–32)
0.63 24.6 ± 4.4
(14–38.4)
23.8 ± 4.1
(14.2–40.9)
0.38
Tumor size (T),
median (range)
1 (1–2) 1 (1–3) 0.56 1 (1–3) 1 (1–3) 0.34
No. of positive lymph nodes,
median (range)
0 (0–23) 0 (0–20) 0.30 0 (0–10) 0 (0–10) 0.90
Tumor grade,
median (range)
mean ± SD
2 (1–3)
1.7 ± 0.6
2 (1–3)
2.0 ± 0.6
0.041* 2 (1–3)
2.0 ± 0.5
2 (1–3)
1.8 ± 0.6
0.051
Ki67 LI (%),
median (range)
mean ± SD
10.1
(0–62.7)
13.3 ± 13.6
12.2
(1.2–61.3)
15.1 ± 13.1
0.46 10.3
(2.0–52.7)
13.7 ± 10.3
7.5
(0.1–35.3)
10.2 ± 8.1
0.03*
ER (%),
median (range)
mean ± SD
90
(40–100)
83.2 ± 18.9
80
(10–100)
68.6 ± 29.1
0.025* 90
(10–100)
79.9 ± 24.1
90
(20–100)
83.1 ± 20.3
0.40
PgR (%),
median (range)
mean ± SD
90
(0–100)
65.5 ± 37.0
80
(0–100)
62.8 ± 34.7
0.44 10
(0–100)
27.7 ± 32.1
20
(0–100)
30.9 ± 31.1
0.37
AR (%),
median (range)
mean ± SD
1.0
(0–80)
17.4 ± 23.4
20
(1–90)
28.0 ± 26.8
0.047* 30
(0–95)
33.0 ± 28.9
35
(0–100)
43.6 ± 33.8
0.065
VDR (%),
median (range)
mean ± SD
10
(0–95)
15.4 ± 17.9
10
(0–70)
16.2 ± 17.9
0.91 10
(0–80)
15.7 ± 16.4
20
(0–50)
18.0 ± 13.1
0.13
pAKT (score),
median (range)
mean ± SD
120
(0–300)
146.5 ± 93.4
100
(0–230)
105.5 ± 76.9
0.14 100
(0–300)
110.2 ± 79.1
70
(0–290)
75.5 ± 65.8
0.0049*
pER (%),
median (range)
mean ± SD
20
(0–90)
25.0 ± 21.3
20
(1–95)
23.1± 21.5
0.74 15
(0–90)
17.8 ± 17.8
20
(0–90)
23.4 ± 18.0
0.018*

LI: labeling index; pAKT: AKT phospho-Ser473; pER: ERα phospho-Ser167.

*P < 0.05 is considered significant.